Literature DB >> 21185773

Kinetics of Epstein-Barr virus load and virus-specific CD8+ T cells in acute infectious mononucleosis.

Yo Hoshino1, Kazuo Nishikawa, Yoshinori Ito, Kiyotaka Kuzushima, Hiroshi Kimura.   

Abstract

BACKGROUND: During the convalescent phase of acute infectious mononucleosis (AIM), Epstein-Barr virus (EBV) load shrinks rapidly in association with a rapid decline in the number of EBV-specific CD8(+) T cells. The actual contribution of EBV-specific CD8(+) T cells in reducing EBV load, however, is not known.
OBJECTIVES: To clarify the impact of EBV-specific CD8(+) T cells on the contraction of EBV load in AIM, we estimated half-lives of both EBV load and EBV-specific CD8(+) T cells. STUDY
DESIGN: Blood was serially taken from five pediatric patients with AIM during the convalescent period, including the very early phase, and both EBV load and EBV-specific CD8(+) T cell numbers were assayed.
RESULTS: EBV load declined rapidly (half-life 1.5 d) during the first 2 weeks after onset of symptoms. This half-life was seven-fold shorter than that reported for CD27(+) memory B cells. Subsequently, the EBV load declined much more slowly, with a half-life of 38.7 d. EBV-specific CD8(+) T cell numbers also declined concomitantly with the decrease in EBV load. The half-life of EBV-specific CD8(+) T cells during first 2 weeks was 2.9 d. The number of EBV-specific CD8(+) T cells and the rate of change of viral load correlated significantly (R(2) ≥ 0.8; p ≤ 0.02).
CONCLUSIONS: The short half-life of EBV load, together with the strong correlation between the number of EBV-specific CD8(+) T cells and the rate of change of viral load indicates an active role for EBV-specific CD8(+) T cells in elimination of EBV in AIM.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 21185773     DOI: 10.1016/j.jcv.2010.11.017

Source DB:  PubMed          Journal:  J Clin Virol        ISSN: 1386-6532            Impact factor:   3.168


  2 in total

1.  Severe EBV hepatitis treated with valganciclovir.

Authors:  R Pisapia; A Mariano; A Rianda; A Testa; A Oliva; L Vincenzi
Journal:  Infection       Date:  2012-07-27       Impact factor: 3.553

2.  Asymptomatic Primary Infection with Epstein-Barr Virus: Observations on Young Adult Cases.

Authors:  Rachel J Abbott; Annette Pachnio; Isabela Pedroza-Pacheco; Alison M Leese; Jusnara Begum; Heather M Long; Debbie Croom-Carter; Andrea Stacey; Paul A H Moss; Andrew D Hislop; Persephone Borrow; Alan B Rickinson; Andrew I Bell
Journal:  J Virol       Date:  2017-10-13       Impact factor: 5.103

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.